AI-Native Scoping Reviews & Evidence Mapping

This paper shows that carotid-related stroke is not primarily a story of narrowing alone, but of vulnerable plaque biology, hidden high-risk lesions, and smarter individualized selection between medical therapy, surgery, and stenting. The full review is worth reading because it maps where modern carotid care is genuinely shifting, from stenosis percentage toward plaque-driven, multimodal stroke risk stratification.

Blue toe syndrome is not just a toe finding — it is a warning signal for distal microembolization, systemic vascular risk, and hidden hematologic, autoimmune, malignant, procedural, or mechanical causes. This SAIMSARA evidence map turns scattered case-level and cohort evidence into a structured diagnostic and treatment roadmap for clinicians and AI agents needing citation-linked BTS reasoning.

Behçet’s disease is far more than recurrent mouth ulcers: this evidence map shows it as a whole-body inflammatory vasculitis that can threaten vision, veins, arteries, brain, gut, and quality of life. The full review explains which diagnostic signals, genetic mimics, and modern therapies — especially anti-TNF agents, apremilast, colchicine, and emerging JAK inhibitors — may change how Behçet’s disease is recognized and treated.

This review maps 29 original studies comparing barefoot, minimalist, mobility, and conventional footwear across gait biomechanics, foot morphology, stability, knee loading, and performance. It shows where barefoot-like footwear may be useful — fall-risk stability, intrinsic foot strength, and knee OA load reduction — and where conventional shoes still matter, especially for impact moderation and postoperative walking capacity.

This review turns 1,815 original studies and 919,224 participants into a structured evidence map showing when barefoot walking/running may improve mechanics, balance, foot strength, or knee loading — and when it becomes clinically risky. It is especially useful for clinicians, runners, coaches, and researchers who need a clear, citation-linked map of barefoot biomechanics, diabetic-foot risk, falls, infection exposure, and safe transition strategies.

The main message of this paper is that current treatment of atherosclerosis relies mainly on standard preventive therapies—cholesterol lowering, combination lipid therapy, and blood-pressure control—whereas future treatment may come from more precise targeting of inflammation, endothelial injury, oxidative stress, immune pathways, and plaque biology. The review maps 47 original research topics, from combination therapies to cannabinoid receptor modulation, and 10 recurrent directions in the non-original literature, from lipid reduction to personalized imaging of plaque burden.

This review shows that atherosclerosis is not merely a late-life clinical disease, but a widespread silent substrate detectable across middle age, inflammatory disease, metabolic risk, genetic susceptibility, and even apparently low-risk populations. The full paper is worth reading because it maps where conventional risk scores may underestimate real vascular burden—and where selective imaging could redefine prevention.

This paper shows that asymptomatic carotid stenosis is no longer a simple “operate-or-observe” problem: under modern medical therapy stroke risk is often lower than once feared, yet a biologically high-risk subgroup still emerges through plaque vulnerability, hemodynamic failure, microemboli, and covert brain injury. The full review is worth reading because it maps where intervention may still matter, where overtreatment is likely, and how the field is shifting from stenosis percentage alone toward truly individualized risk stratification.

This review shows where clopidogrel truly outperforms aspirin, where the advantage disappears, and why the answer changes across PCI, stroke, PAD, gastrointestinal risk, and surgery. It turns a common everyday antiplatelet choice into a clinically practical evidence map of who may benefit more from clopidogrel, when aspirin may still be safer, and where the real uncertainties remain.

This review maps 995 original studies and 26.6 million participants comparing apixaban and rivaroxaban across AF, VTE, CKD, cirrhosis, cancer, elderly, and other high-risk populations. It delivers a clear human- and machine-ready signal: apixaban shows a more favorable bleeding profile, while rivaroxaban remains relevant in selected adherence, cost, VTE, and orthopedic contexts.

This review shows that aortic dissection treatment is no longer a simple “Type A surgery, Type B medicine” paradigm: outcomes now depend on timing, anatomy, malperfusion, remodeling strategy, and lifelong surveillance. The full paper is worth reading because it maps where TEVAR, open surgery, hybrid repair, medical stabilization, and emerging pharmacological strategies truly change survival—and where uncertainty still demands careful patient selection.

Aortic dissection is not predicted by diameter alone: hypertension, genetics, aortic geometry, pregnancy, medications, sleep apnea, inflammation, and environmental triggers all reshape individual risk. The full paper is worth reading because it maps where classic thresholds fail — and where modern risk stratification may prevent missed catastrophic events.